In this respect, TME is now considered to be a good target for anticancer therapies, as it provides the opportunity to perturb the delicate balance that promotes tumor progression.
Finally, because VHR is regulated during cell cycle progression and because its suppression by RNAi[ 3] halts cellular proliferation and induces cellular senescence, and, more importantly, because of its overexpression in the cervix cancer, we propose that VHR may be a good target for anticancer therapy.
Although the EAF inhibited the growth of cancer cells only at higher concentrations (25 and 50 mg/kg), it exhibited comparable anticancer activity with bleomycin (Table 2), hence EAF might be a good source for isolating anticancer agent.
Many client proteins of Hsp90 are involved in tumor progression and survival and therefore Hsp90 can be a good target for developing anticancer drugs.
He agrees that the interface between the two proteins would be a good place to focus anticancer drugs.
MBS extract was shown to be a good inducer for both anticancer cytokines, i.e., TNF-α and IFN-β in culture supernatants of HeLa and HepG2 cells.
We showed that ANO1 is overexpressed at the RNA and protein levels in HNSCC, predicted that ANO1 is a membrane protein, and also suggested that it might be a good candidate for targeted anticancer therapy (Carles et al, 2006).
Our results suggest that DCM fraction of hydroalcoholic extract of P. kurroa might be a good candidate for development as anticancer drug and may come out as a new future phytopharmaceutical drug since inclusion of phytopharmaceuticals/enriched fractions is already in the process in several pharmacopoeias.
For a molecule to be a good candidate as a target for anticancer therapy, several criteria must be fulfilled.
Most of the in vitro and preclinical studies have revealed that mistletoe might be a good candidate for development of an anticancer drug [ 50– 62].
